Tag Archives: gild

Gilead, AbbVie Hep C Price Cuts Seen Hitting Sales

As the price war over the new hepatitis C drugs heats up, the 2015 consensus estimates for both may be too high, according to Deutsche Bank. In two separate notes Tuesday and Wednesday, analyst Robyn Karnauskas calculated the prospects for AbbVie’s (ABBV) Viekira Pak and Gilead Sciences’ (GILD) Harvoni and Sovaldi after the two companies announced a series of exclusive agreements with payers and pharmacy benefit managers. “ABBV has so far nailed

Gilead, AbbVie Hepatitis C Price Cuts Will Hit Sales

As the price war over the new hepatitis C drugs heats up, the 2015 consensus estimates for both may be too high, according to Deutsche Bank. In two separate notes Tuesday and Wednesday, analyst Robyn Karnauskas calculated the prospects for AbbVie’s (ABBV) Viekira Pak and Gilead Sciences’ (GILD) Harvoni and Sovaldi after the two companies announced a series of exclusive agreements with payers and pharmacy benefit managers. “ABBV has so far nailed

Aetna Sides With Gilead In Hepatitis C Drug Battle

Gilead Sciences (GILD) picked up another provider for its hepatitis C drugs Friday in the ongoing battle for market share in that disease. Giant health insurer Aetna announced on its website that “Harvoni and Sovaldi will now be preferred therapies for Aetna Commercial customers” after the two companies negotiated an unspecified discount on the drugs’ prices. Officially, Sovaldi, which is usually taken with at least one other drug, costs $84,000